1001 related articles for article (PubMed ID: 7802562)
41. Hodgkin's disease, intracranial involvement. Report of a case and review of the literature.
Vera R; Enriquez R; Papac R
Am J Clin Oncol; 1985 Feb; 8(1):73-6. PubMed ID: 3838852
[TBL] [Abstract][Full Text] [Related]
42. [CVP or C-MOPP combination chemotherapy in the treatment of advanced Hodgkin's disease and non-Hodgkin's lymphoma (intermediate grade of working formulation)].
Sampi K; Honda T; Hattori M
Rinsho Ketsueki; 1984 Feb; 25(2):164-8. PubMed ID: 6547984
[No Abstract] [Full Text] [Related]
43. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
44. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
[TBL] [Abstract][Full Text] [Related]
45. Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease. Evidence for a dendritic or B cell derivation?
Pinkus GS; Pinkus JL; Langhoff E; Matsumura F; Yamashiro S; Mosialos G; Said JW
Am J Pathol; 1997 Feb; 150(2):543-62. PubMed ID: 9033270
[TBL] [Abstract][Full Text] [Related]
46. The interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas.
Jaffe ES; Zarate-Osorno A; Kingma DW; Raffeld M; Medeiros LJ
Ann Oncol; 1994; 5 Suppl 1():7-11. PubMed ID: 8172822
[TBL] [Abstract][Full Text] [Related]
47. Coexistence of nodular lymphocyte predominance Hodgkin's disease and Hodgkin's disease of the usual type.
Gelb AB; Dorfman RF; Warnke RA
Am J Surg Pathol; 1993 Apr; 17(4):364-74. PubMed ID: 8494105
[TBL] [Abstract][Full Text] [Related]
48. Expression of enolases in T cell tumors and Hodgkin's disease.
Oka K; Mori N; Haimoto H; Kato K
Lab Invest; 1990 Dec; 63(6):792-7. PubMed ID: 2255187
[TBL] [Abstract][Full Text] [Related]
49. Pleomorphic medium-sized T-cell lymphoma following Hodgkin's disease (nodular sclerosis type).
Gaulier A; Teillet F; Davi F; Couturier J; Laye S; Raphael M
Arch Pathol Lab Med; 1997 Apr; 121(4):411-6. PubMed ID: 9140313
[TBL] [Abstract][Full Text] [Related]
50. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
51. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
52. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
53. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
Petera J; Macharová H; Pohanková R; Malír A; Coupek P; Konecný M; Patera J; Pecina J; Drbal J; Koukalová H; Vásová I
Neoplasma; 2000; 47(2):129-32. PubMed ID: 10985481
[TBL] [Abstract][Full Text] [Related]
54. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M;
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834
[TBL] [Abstract][Full Text] [Related]
55. Cancer of the oropharynx developed after radiotherapy and chemotherapy for Hodgkin's disease--a case report.
Mohiuddin MG; Sakai K; Tsuchida E; Inakoshi H
Radiat Med; 1992; 10(1):30-3. PubMed ID: 1585000
[TBL] [Abstract][Full Text] [Related]
56. Nodular lymphocyte predominance Hodgkin's disease: a monoclonal or polyclonal B-cell disorder?
Pan LX; Diss TC; Peng HZ; Norton AJ; Isaacson PG
Blood; 1996 Mar; 87(6):2428-34. PubMed ID: 8630407
[TBL] [Abstract][Full Text] [Related]
57. [Clinical features and treatment of Hodgkin's disease].
Shirakawa S; Kita K; Kobayashi T; Ohno T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):421-34. PubMed ID: 3754108
[TBL] [Abstract][Full Text] [Related]
58. Composite B-cell and T-cell lymphoma arising 24 years after nodular lymphocyte predominant Hodgkin's disease.
Hancock JC; Wells A; Halling KC; Tilashalski K; Conner MG; Johns C; Listinsky CM
Ann Diagn Pathol; 1999 Feb; 3(1):23-34. PubMed ID: 9990110
[TBL] [Abstract][Full Text] [Related]
59. [The diagnosis and treatment of giant-cell histiocytic non-Hodgkin's lymphoma].
Sivkovich SA; Kindzel'skiĭ LP; Galakhin KA
Vrach Delo; 1990 Apr; (4):60-3. PubMed ID: 2275171
[TBL] [Abstract][Full Text] [Related]
60. Simultaneous presentation of relapsing Hodgkin's disease and treatment-related non-Hodgkin's lymphoma.
Perri RT; Allen JI; Oken MM; Limas C; Kay NE
Med Pediatr Oncol; 1985; 13(3):122-5. PubMed ID: 3838792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
